Cynata Therapeutics

Ross Macdonald, Ph.D., CEO

April 20 | 11:00am | Gaudi 3 Ballroom

Melbourne, Australia

(ASX: CYP)

In-Person Presentation

Cynata Therapeutics is a clinical-stage regenerative medicine company developing a therapeutic mesenchymal stem cell platform technology, Cymerus™, utilizing induced pluripotent stem cells. A successful world-first clinical trial in graft-versus-host disease met all safety and efficacy endpoints with a Phase II trial expected to commence in the U.S. in 2022. A Phase III clinical trial in osteoarthritis and a Phase I/II clinical trial in COVID-19 commenced in 2020 and a Phase I/II trial in diabetic foot ulcers will commence in late 2021. The company’s major shareholders include BioScience Managers, a leading global healthcare institutional investor, Fidelity, and Fujifilm. The company’s proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor derived MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale.

www.cynata.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions